Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, October 01, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Illumina Introduces the HiSeq X™ Ten Sequencing System
Thursday, January 16, 2014
Breaks barriers with world's first $1,000 genome, enables 'factory' scale sequencing for population and disease studies.

Illumina Launches the NextSeq™ 500 Sequencing System
Thursday, January 16, 2014
Transformative addition to industry-leading portfolio brings whole genome sequencing to the desktop.

Massachusetts General Hospital Adopts Advanced Analytical Technology in Fight Against Cancer
Thursday, January 16, 2014
Company's Fragment Analyzer evaluates DNA and RNA of cancer patients.

New Improved Thermoelectrically Cooled MPPC for Photon Counting Applications
Tuesday, December 24, 2013
New S12576-050 and S12577-050 multi-pixel photon counter devices from Hamamatsu.

Agilent Introduces Two New ScreenTape Assays
Wednesday, December 18, 2013
Two new assays to optimize next-generation sequencing quality control, performance, throughput.

Modifying the Oligo Backbone - Advice for PNA and UNA Chemistry
Tuesday, December 10, 2013
Link Technologies provides key protocols for oligonucleotide synthesis and modification.

New Whitepaper Highlights Impact of NGS Target Enrichment Assay Choice
Tuesday, December 03, 2013
OGT provides insight on NGS enrichment optimization.

Integrated DNA Technologies Launches xGen® Universal Blocking Oligos
Tuesday, November 26, 2013
Enhancing the performance of target capture experiments.

Oversubscribed NGS and aCGH Workshop Now Available Online
Tuesday, November 26, 2013
OGT’s ASHG 2013 workshop highlights the need for comprehensive genomic analysis.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 206
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv